by Neoteryx, on October 13,2021
October 2021 — The Science History Institute (the Institute) has announced Fasha Mahjoor as the recipient of the 21st annual Pittcon Heritage Award. Mahjoor is the founder and CEO of …
Read Storyby Neoteryx, on October 4,2021
ZA Approval of Mitra® Devices for Remote Specimen Collection at Home Gives Citizens Living in Rural Areas Greater Access to Critical Lab Services Los Angeles, USA & South Africa — …
Read Storyby Neoteryx, on September 23,2021
September 2021 — According to a preprint article slated for publication in the next issue of the journal Bioanalysis, the COVID-19 pandemic led to a shift in the way blood …
Read Storyby Neoteryx, on August 18,2021
Los Angeles, USA & Beijing, CHINA — The Mitra® microsampling device from US-based Neoteryx is now registered as a Class I in vitro diagnostic (IVD) medical device with the Chinese …
Read Storyby Neoteryx, on August 3,2021
AUGUST 2021 — According to a news item from Peit Kreuzer reporting in Germany for Deutschlandfunk, doping in sports is dominating the headlines as global sports agencies consider new and …
Read StoryThe latest product releases, company news and microsampling industry updates from Neoteryx.
If you don’t find the information & assets you need via the buttons below, please contact us here: press@neoteryx.com
Fact Sheet & FAQs
© Neoteryx 2021 | Privacy Policy | Sitemap
421 Amapola Ave
Torrance, CA 90501
This site is protected by reCAPTCHA and the Google Privacy
Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.
Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.